Indaptus Q3 2023 net loss $0.47/share; cash $16M into Q2 2024; Decoy20 all 4 patients stable disease

Indaptus Therapeutics, Inc.

2023-Q3 EPS reported -$1.36

Cash and equivalents $16.0M as of Sep 30, 2023, down from $26.4M at Dec 31, 2022; runway into Q2 2024.
Net loss per share $0.47 for Q3 2023 versus $0.42 year ago; R&D expense $2.2M (up $0.6M YoY).
Decoy20 Phase 1 first cohort: all four patients maintain stable disease; first patient dosed in second cohort.
Roger Waltzman, M.D. appointed Chief Medical Officer effective August 7, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Indaptus Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: EPS approximately $0.47.

Period: the third quarter ended September 30, 2023
EPS: approximately $0.47
Result: reported results

Exact text from the filing

On November 6, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039517

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.